• Explore /
  • Poster
  • / Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

Jonathan M. Loree

Jonathan M. Loree

BC Cancer, Vancouver, BC, Canada

Jonathan M. Loree , James T. Topham , Hagen Fritz Kennecke , Harriet Feilotter , Young S Lee , Shakeel Virk , Scott Kopetz , Dzifa Yawa Duose , Ganiraju C. Manyam , Jeffrey S Morris , Dipen M. Maru , Daniel Renouf , Derek J. Jonker , Dongsheng Tu , Christopher J. O'Callaghan , Eric Xueyu Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02870920

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3551)

DOI

10.1200/JCO.2022.40.16_suppl.3551

Abstract #

3551

Poster Bd #

345

Abstract Disclosures

Similar Posters

First Author: Eric Xueyu Chen

First Author: Eric Xueyu Chen

First Author: Lucy Xiaolu Ma

First Author: Tharani Krishnan